Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université De Rennes 1

Universitë De Bordeaux

Centre Hospitalier Universitaire De Bordeaux

Institut Bergonie

Université De Rennes I

Pierre Van De Weghe

Patrick Legembre

Pierre Vacher

Amélie Fouque

Patrick Blanco

Mickael Jean

The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility

The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.

PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof

Growing community of inventors

Rennes, France

Pierre Van De Weghe